154 results on '"Nordström, Dan C."'
Search Results
2. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies
3. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor:results from 13 European registries
4. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept:Results from the international TOCERRA and PANABA observational collaborative studies
5. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)
6. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
7. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
8. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries
9. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
10. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis:48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
11. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis:results from five Nordic biologics registries
12. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48- week clinical and radiographic results of the investigatorinitiated randomised controlled NORD- STAR trial.
13. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries
14. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries
15. IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IκBζ-dependent induction of ELF3
16. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
17. After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
18. IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IκBζ-dependent induction of ELF3.
19. Activation of histamine H4 receptor inhibits TNFα/IMD-0354-induced apoptosis in human salivary NS-SV-AC cells
20. Rituximab done: what’s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
21. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers
22. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents:results from a collaboration of 16 registries
23. Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)
24. Histamine transport and metabolism are deranged in salivary glands in Sjögren’s syndrome
25. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
26. Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration
27. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
28. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
29. Tumor necrosis factor primes and metal particles activate the NLRP3 inflammasome in human primary macrophages
30. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis
31. Anakinra in the treatment of rheumatoid arthritis and other IL-1-driven conditions
32. Is one year early, or too late? Comment on the article by Tak et al
33. Truncating NFKB1variants cause combined NLRP3 inflammasome activation and type I interferon signaling and predispose to necrotizing fasciitis
34. Haploinsufficiency of A20 impairs protein–protein interactome and leads into caspase-8-dependent enhancement of NLRP3 inflammasome activation
35. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
36. Occurrence Of Different Ensuing Triggering Infectioins Preceding Reactive Arthritis: A Follow Up Study
37. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers
38. Toll-like receptors and their soluble forms differ in the knee and thumb basal osteoarthritic joints
39. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort:data from the CERERRA collaboration
40. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis:results from a European collaborative study
41. Correlations between macrophage polarizing cytokines, inflammatory mediators, osteoclast activity, and toll‐like receptors in tissues around aseptically loosened hip implants
42. Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
43. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
44. The EULAR Study Group for Registers and Observational Drug Studies:comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers
45. Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis
46. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study
47. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
48. Rituximab done: what’s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
49. Correlations between macrophage polarizing cytokines, inflammatory mediators, osteoclast activity, and toll-like receptors in tissues around aseptically loosened hip implants.
50. Toll-like receptors in human chondrocytes and osteoarthritic cartilage
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.